Abstract
Background
To evaluate the second malignant tumors (SMTs) and non-tumor causes of death among patients diagnosed with localized and regional kidney cancer.
Methods
Patients diagnosed with kidney cancer between 2000 and 2017 in the Surveillance, Epidemiology, and End Results (SEER) program database were identified. All causes of death for patients during the follow-up and standardized mortality ratio (SMR) were analyzed.
Result
113,734 patients with localized kidney cancer with 30,390 cases of death were analyzed. 60.4% of the death cases were due to non-tumor caused and 23.6% were second malignant tumors (SMTs). Main SMTs included cancers of lung and bronchus [n = 1,283, SMR: 1.00 (0.95–1.06)] and pancreas [n = 393, SMR: 1.27 (1.15–1.41)]. Causes of death for non-tumor mainly included heart diseases [n = 6,161, SMR: 1.25 (1.21–1.28)] and chronic obstructive pulmonary disease (COPD) [n = 1,185, SMR: 0.99 (0.94–1.05)]. 14,437 of 29,602 patients with regional kidney cancer died. 14.6% of all deaths were due to SMTs and 23.6% due to non-tumor causes. Main SMTs contained bladder cancer [n = 371, SMR: 10.90 (9.81–12.06)] and lung and bronchus cancer [n = 346, SMR: 1.21 (1.08–1.34)]. The main non-tumor death was heart disease [n = 1,424, SMR: 1.26 (1.2–1.33)]. When stratified by pathological types, patients with clear cell renal cell carcinoma (RCC) did not have increased mortality risks of bladder cancer and lung cancer but patients with non-clear cell RCC did.
Conclusion
SMTs and non-tumor diseases including lung and bronchus cancer, bladder cancer, pancreas cancer, diseases of heart, COPD, and cerebrovascular diseases are the leading causes of death besides kidney cancer and should be paid more attention during patients’ survival period.
Supplementary Information
The online version contains supplementary material available at 10.1186/s40001-023-01176-6.
Keywords: Kidney cancer, SMT, Non-tumor causes of death, Localized, Regional, SEER
Introduction
Kidney cancer, the 13th most common malignant tumor in the world, accounts for 2.4% of all malignant tumor cases [1]. It is estimated that there are about 79,000 new cases of kidney cancer and 13,920 deaths globally in 2022 [2]. The incidence of kidney cancer has been increasing globally at an annual rate of approximately 2–3% since the 1970s [3]. But its mortality rate has remained stable since the 1990s [4]. Most newly diagnosed cases are at the localized stage and are potentially curative by surgical resection with an excellent survival outcome [5, 6]. For the treatment of localized renal cell cancer (RCC), partial nephrectomy for small tumors and radical nephrectomy for large tumors remains gold standard treatments. Many factors like patients’ age, tumor size is, and ischemia time that could affect postoperative renal function, quality of life and even the survival outcomes [7, 8]. The survival of patients with regional or distant metastasis kidney cancer was also greatly improved with the continuous optimization of treatment regimens. The 5-year overall survival for kidney cancer patients has also been improved from 57% in the late 1980s to > 70% in recent years [9].
The etiologies of kidney cancer include genetic factors, environmental and occupational exposure, medical history, lifestyle, and other factors [1]. Some of them may also contribute to the development of second malignant tumors (SMTs). In addition, the incidence of kidney cancer increases with age, and is prone to occur in the elderly [4]. Elderly patients are more likely to have comorbidities that increase their risk of dying from some underlying diseases like hypertension, coronary heart disease, etc. It is meaningful to explore all causes of death and related mortality risks for kidney cancer patients. To the best of our knowledge, no study in the current literature has evaluated the causes of death from SMTs and non-neoplastic diseases among kidney cancer patients. In this study, we aimed to evaluate all causes of death (kidney cancer, SMTs, and non-tumor diseases) for patients with localized and regional kidney cancer, and to calculate the mortality risks of each cause compared with the general population.
Materials and methods
Data sources
The data of the retrospective cohort study were obtained from the Surveillance, Epidemiology, and End Results (SEER) program database, which provides information on population-based cancer incidence and survival data from approximately 28% of the US population. The mortality data of the general population during 2000–2017 were drawn from the National Center for Health Statistics. The kidney cancer incidence and mortality of the Americans were from the Global Cancer Observatory (GCO) which is based on the GLOBOCAN estimates of incidence, mortality and prevalence in 185 countries or territories for 36 cancer types.
Study population and study variables
Patients who were diagnosed with kidney cancer according to ICD-O-3/WHO 2008 definition between 2000 and 2017 were included. Inclusion criteria: ① kidney cancer was the only one or the first of multiple primary malignant tumors; ② all patients had definite staging and pathological information; ③ the follow-up time, living status (alive or dead), and the detailed causes of death were clear. Exclusion criteria: ① patients with synchronous multiple tumors with the cutoff of 2 months in accordance with SEER criteria [10]; ② the follow-up time was 0; ③ patients died within 2 months after the diagnosis of kidney cancer.
For included patients, the following demographic and clinical variables were collected: age at diagnosis (15–44 years, 45–54 years, 55–64 years, 65–74 years, 75 + years), year of diagnosis (2000–2006, 2007–2012, and 2013–2017), race (white, black, and others), grade (well differentiated, moderate differentiation, poor differentiation, and undifferentiated), main pathological type, surgical therapy (partial nephrectomy, radical nephrectomy, local tumor destruction), chemotherapy (yes, no/unknown). The last follow-up time was December 31, 2018.
Outcome assessments
Our study evaluated all causes of death that were identified from death codes in the SEER. The mortality risks were assessed by the standardized mortality ratio (SMR), which was calculated by comparing the observed number of deaths to the expected one. The expected number of deaths was based on the total person-year of included patients and the mortality rate of all causes of death among the general population.
All causes of death and related SMR were regarded as the primary outcomes of our study. The incidence and mortality from 2000 to 2017, estimated incidence and mortality up to 2040 and rates in different age groups were defined as the second outcomes.
Statistical analyses
Patients were segregated into two groups according to their stage information (localized or regional). With the incidence-SEER research data, 18 registries database and standardized incidence ratios tables function in the SEER*Stat 8.40 software, we analyzed all causes of death (114 items) and calculated SMRs with its 95% confidence intervals (95%CI) with the exact method of statistics. The various mortality rates of the US general population were extracted from the National Center for Health Statistics that was available through the SEER program. We also estimated their SMRs and 95%CI for patients with different pathological types (clear cell RCC or non-clear RCC) and different survival times after diagnosis (< 5 years, 5–10 years, > 10 years). The mortality rates were calculated by the death of different causes and total number of patients each year during the follow-ups. P < 0.05 was considered to be statistically significant.
Results
A total of 143,336 patients were identified, and 44,827 of them died during the follow-up. The majority of patients (n = 113,734) had localized disease with a total mortality rate of 27% (n = 30,390). 29,602 patients were in the regional stage whose mortality rate was 49% (n = 14,437). The baseline characteristics of all patients and all deaths in localized and regional stages are presented in Table 1.
Table 1.
Baseline characteristics of included patients
| Variables | Localized | Regional | ||||
|---|---|---|---|---|---|---|
| Patients, n | Deaths, n | SMR (95% CI) | Patients, n | Deaths, n | SMR (95% CI) | |
| Total | 11,3734 | 30,390 | 1.59# (1.57–1.6) | 29,602 | 14,437 | 3.36# (3.31–3.42) |
| Age | ||||||
| 15–44 years | 13,137 | 1,041 | 3.24# (3.04–3.44) | 1,843 | 607 | 17.15# (15.82–18.57) |
| 45–54 years | 22,692 | 3,265 | 2.44# (2.35–2.52) | 4,646 | 1,739 | 8.07# (7.7–8.46) |
| 55–64 years | 31,595 | 6,713 | 1.97# (1.93–2.02) | 7,958 | 3,361 | 5.04# (4.87–5.21) |
| 65–74 years | 27,606 | 8,969 | 1.51# (1.48–1.54) | 8,112 | 4,222 | 3.17# (3.07–3.26) |
| 75 + years | 17,619 | 10,361 | 1.27# (1.25–1.3) | 6,246 | 4,451 | 2.18# (2.12–2.25) |
| Sex | ||||||
| Male | 69,116 | 18,873 | 1.56# (1.54–1.59) | 19,456 | 9,371 | 3.22# (3.15–3.28) |
| Female | 44,618 | 11,517 | 1.62# (1.59–1.65) | 10,146 | 5,066 | 3.67# (3.57–3.77) |
| Year of diagnosis | ||||||
| 2000–2007 | 39,932 | 18,042 | 1.58# (1.55–1.6) | 11,362 | 7,905 | 3.16# (3.09–3.23) |
| 2008–2012 | 34,484 | 8,521 | 1.57# (1.54–1.61) | 8,553 | 4,133 | 3.43# (3.33–3.54) |
| 2013–2017 | 39,318 | 3,827 | 1.67# (1.61–1.72) | 9,687 | 2,399 | 4.10# (3.94–4.27) |
| Race | ||||||
| White | 92,846 | 24,884 | 1.52# (1.51–1.54) | 25,262 | 12,322 | 3.20# (3.15–3.26) |
| Black | 14,168 | 4,073 | 1.86# (1.81–1.92) | 2,400 | 1,274 | 4.61# (4.36–4.87) |
| American Indian-Alaska Native | 891 | 247 | 4.19# (3.69–4.75) | 237 | 97 | 6.43# (5.21–7.84) |
| Asian or Pacific Islander | 5,829 | 1,186 | 2.04# (1.93–2.16) | 1,703 | 744 | 4.84# (4.5–5.21) |
| Grade | ||||||
| Well differentiated | 11,586 | 2,302 | 1.39# (1.33–1.45) | 1,102 | 465 | 2.11# (1.92–2.31) |
| Moderately differentiated | 42,645 | 7,706 | 1.33# (1.3–1.36) | 7,879 | 3,059 | 2.15# (2.07–2.22) |
| Poorly differentiated | 18,250 | 4,089 | 1.62# (1.57–1.67) | 9,432 | 4,718 | 3.60# (3.5–3.71) |
| Undifferentiated | 3,213 | 1,147 | 2.48# (2.34–2.62) | 5,275 | 3,164 | 5.68# (5.48–5.88) |
| Pathological type | ||||||
| Papillary | 13,202 | 2,996 | 1.38# (1.33–1.43) | 1,691 | 758 | 2.91# (2.71–3.13) |
| Chromophores | 6,352 | 908 | 0.92# (0.86–0.98) | 1,005 | 254 | 1.67# (1.47–1.88) |
| Clear cell | 58,472 | 12,549 | 1.47# (1.45–1.5) | 14,201 | 5,660 | 2.85# (2.78–2.93) |
| Surgical treatment | ||||||
| Partial nephrectomy | 33,344 | 3,535 | 1.02 (0.99–1.06) | 2,339 | 569 | 1.60# (1.47–1.74) |
| Radical nephrectomy | 48,672 | 11,929 | 1.61# (1.58–1.64) | 24,595 | 11,902 | 3.27# (3.21–3.33) |
| Local tumor destruction | 5,983 | 1,527 | 1.35# (1.29–1.42) | 128 | 78 | 3.44# (2.72–4.29) |
| Surgery, NOS | 933 | 260 | 1.63# (1.44–1.84) | 410 | 215 | 3.22# (2.81–3.69) |
| No | 7,084 | 3,933 | 3.11# (3.01–3.21) | 1,551 | 1,328 | 9.84# (9.31–10.38) |
| Chemotherapy | ||||||
| Yes | 1,732 | 453 | 5.29# (4.81–5.8) | 3,562 | 1,841 | 8.96# (8.55–9.38) |
| No/unknown | 112,002 | 29,937 | 1.57# (1.55–1.59) | 26,040 | 12,596 | 3.08# (3.03–3.14) |
SMR standardized mortality ratio, CI confidence interval, NOS not otherwise specified
#Statistical significance with P < 0.05
The incidence and mortality among patients with kidney cancer from 2000 to 2017 as well as the estimated number of incidence and mortality up to 2040 are presented in Fig. 1A and B. The newly diagnosed cases in different stages showed that the increasing incidence of total kidney cancer was mainly due to the increase of localized diseases (Fig. 1C). The mortality remained stable from 2000 to 2017 as well as in the estimated future. The incidence and mortality of patients with different ages between 2000 and 2017 are presented in Fig. 1D.
Fig. 1.
The incidence and mortality of kidney cancer in the United States. A Kidney cancer incidence and mortality, 2000–2017. B Estimated incidence and mortality of kidney cancer patients in 2020–2040. C The number of new kidney cancer cases diagnosis in different stages from 2000 to 2017. D Incidence and mortality of kidney cancer patients in different age groups
Causes of death for patients with localized disease
A total of 113,734 patients with localized kidney cancer were identified, and 30,390 of them died. 15,553(51.2%) of all deaths occurred within 5 years, 9,603(31.6%) and 5,234(17.2%) deaths were observed in the periods of 5–10 years and > 10 years after diagnosis. Kidney cancer deaths only accounted for 23.6% of all deaths, SMTs accounted for 16.0% and the remaining 60.4% were due to non-tumor causes. Main SMTs included cancer from the lung and bronchus [n = 1,283, SMR: 1.00 (0.95–1.06)], pancreas [n = 393, SMR: 1.27 (1.15–1.41)], colon and rectum [n = 315, SMR: 0.78 (0.7–0.87)], liver and intrahepatic bile duct [n = 275, SMR: 1.50 (1.33–1.69)], and urinary bladder [n = 277, SMR: 1.95 (1.73–2.2)]. The main causes of non-tumor deaths included heart diseases [n = 6,161, SMR: 1.25 (1.21–1.28)], chronic obstructive pulmonary disease (COPD) and allied cond [n = 1,185, SMR: 0.99 (0.94–1.05)], cerebrovascular diseases [n = 1,183, SMR: 1.12 (1.06–1.18)], nephritis, nephrotic syndrome and nephrosis [n = 1,166, SMR: 3.01 (2.84–3.18)], and diabetes mellitus [n = 1,137, SMR: 1.91 (1.8–2.02)]. When stratified by pathological types, RCC patients had significantly lower risk of bladder cancer than these with non-clear RCC, as well as lower lung and bronchus cancer and COPD and allied cond mortality risks. For both patients with clear cell and non-clear cell kidney cancer, there was a significant increase in the SMR of cancer from pancreas, liver and intrahepatic bile duct, as well as brain and other nervous systems. The mortality risk of prostate cancer, colon and rectum cancer decreased significantly. All these results are presented in Table 2, Fig. 2A and Additional file 1. The mortality rates of all causes of death, kidney cancer, SMTs and non-tumor causes are presented in Fig. 3A. There were no significant differences in mortality rate from SMTs and non-neoplastic causes between the clear cell and non-clear cell RCC groups.
Table 2.
Main causes of death for patients with localized kidney cancer
| Causes of death | Total | Clear cell RCC | Non-clear cell RCC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Observed, n | Expected, n | SMR (95% CI) | Observed, n | Expected, n | SMR (95% CI) | Observed, n | Expected, n | SMR (95% CI) | |
| All causes of death | 30,390 | 19,151.73 | 1.59# (1.57–1.6) | 12,549 | 8,512.19 | 1.47# (1.45–1.5) | 17,841 | 10,639.55 | 1.68# (1.65–1.7) |
| All malignant cancers | 12,022 | 4,575.66 | 2.63# (2.58–2.67) | 5,118 | 2,095.27 | 2.44# (2.38–2.51) | 6,904 | 2,480.39 | 2.78# (2.72–2.85) |
| Urinary system | 7,500 | 260.56 | 28.78# (28.14–29.44) | 3,267 | 117.66 | 27.77# (26.82–28.74) | 4,233 | 142.9 | 29.62# (28.74–30.53) |
| Kidney and renal pelvis | 7,161 | 111.5 | 64.22# (62.74–65.73) | 3,220 | 51.54 | 62.48# (60.34–64.67) | 3,941 | 59.96 | 65.73# (63.69–67.81) |
| Urinary bladder | 277 | 141.91 | 1.95# (1.73–2.2) | 44 | 62.87 | 0.70# (0.51–0.94) | 233 | 79.03 | 2.95# (2.58–3.35) |
| Respiratory system | 1,315 | 1,318.67 | 1 (0.94–1.05) | 538 | 606.11 | 0.89# (0.81–0.97) | 777 | 712.56 | 1.09# (1.02–1.17) |
| Lung and bronchus | 1,283 | 1,277.13 | 1 (0.95–1.06) | 529 | 587.53 | 0.90# (0.83–0.98) | 754 | 689.6 | 1.09# (1.02–1.17) |
| Digestive system | 1,276 | 1,176.37 | 1.08# (1.03–1.15) | 566 | 540.52 | 1.05 (0.96–1.14) | 710 | 635.85 | 1.12# (1.04–1.2) |
| Pancreas | 393 | 308.78 | 1.27# (1.15–1.41) | 174 | 143.53 | 1.21# (1.04–1.41) | 219 | 165.25 | 1.33# (1.16–1.51) |
| Colon and rectum | 315 | 403.3 | 0.78# (0.7–0.87) | 140 | 181.26 | 0.77# (0.65–0.91) | 175 | 222.04 | 0.79# (0.68–0.91) |
| Liver and intrahepatic bile duct | 275 | 183.41 | 1.50# (1.33–1.69) | 126 | 86.78 | 1.45# (1.21–1.73) | 149 | 96.63 | 1.54# (1.3–1.81) |
| Male genital system | 183 | 324.19 | 0.56# (0.49–0.65) | 72 | 132.98 | 0.54# (0.42–0.68) | 111 | 191.22 | 0.58# (0.48–0.7) |
| Prostate | 178 | 319.62 | 0.56#(0.48–0.65) | 71 | 130.87 | 0.54# (0.42–0.68) | 107 | 188.74 | 0.57# (0.46–0.69) |
| Brain and other nervous system | 159 | 100.52 | 1.58#(1.35–1.85) | 68 | 49.1 | 1.38# (1.08–1.76) | 91 | 51.42 | 1.77# (1.42–2.17) |
| Leukemia | 190 | 182.42 | 1.04 (0.9–1.2) | 72 | 82.78 | 0.87 (0.68–1.1) | 118 | 99.64 | 1.18 (0.98–1.42) |
| Lymphoma | 148 | 173.82 | 0.85 (0.72–1) | 62 | 79.52 | 0.78# (0.6–1) | 86 | 94.3 | 0.91 (0.73–1.13) |
| Non-tumor causes | |||||||||
| Diseases of heart | 6,161 | 4,945.61 | 1.25# (1.21–1.28) | 2,547 | 2,140.78 | 1.19# (1.14–1.24) | 3,614 | 2,804.84 | 1.29# (1.25–1.33) |
| COPD and allied cond | 1,185 | 1,194.07 | 0.99 (0.94–1.05) | 470 | 543.39 | 0.86# (0.79–0.95) | 715 | 650.67 | 1.10# (1.02–1.18) |
| Cerebrovascular diseases | 1,183 | 1,058.31 | 1.12# (1.06–1.18) | 480 | 455.48 | 1.05 (0.96–1.15) | 703 | 602.83 | 1.17# (1.08–1.26) |
| Nephritis, nephrotic syndrome and nephrosis | 1,166 | 387.89 | 3.01# (2.84–3.18) | 409 | 165.73 | 2.47# (2.23–2.72) | 757 | 222.16 | 3.41# (3.17–3.66) |
| Diabetes mellitus | 1,137 | 595.36 | 1.91# (1.8–2.02) | 488 | 265.59 | 1.84# (1.68–2.01) | 649 | 329.77 | 1.97# (1.82–2.13) |
| Accidents and adverse effects | 668 | 602.41 | 1.11# (1.03–1.2) | 293 | 282.38 | 1.04 (0.92–1.16) | 375 | 320.03 | 1.17# (1.06–1.3) |
| Alzheimer’s | 611 | 701.64 | 0.87# (0.8–0.94) | 242 | 300.21 | 0.81# (0.71–0.91) | 369 | 401.43 | 0.92 (0.83–1.02) |
| Pneumonia and influenza | 489 | 429.8 | 1.14# (1.04–1.24) | 197 | 184.8 | 1.07 (0.92–1.23) | 292 | 245 | 1.19# (1.06–1.34) |
| Hypertension without heart disease | 482 | 223.68 | 2.15# (1.97–2.36) | 192 | 96.06 | 2.00# (1.73–2.3) | 290 | 127.62 | 2.27# (2.02–2.55) |
| Septicemia | 406 | 285.54 | 1.42# (1.29–1.57) | 164 | 125.48 | 1.31# (1.11–1.52) | 242 | 160.05 | 1.51# (1.33–1.71) |
| Chronic liver disease and cirrhosis | 293 | 220.44 | 1.33# (1.18–1.49) | 149 | 110.01 | 1.35# (1.15–1.59) | 144 | 110.44 | 1.30# (1.1–1.54) |
| Suicide and self-inflicted injury | 151 | 153.78 | 0.98 (0.83–1.15) | 83 | 78.18 | 1.06 (0.85–1.32) | 68 | 75.61 | 0.9 (0.7–1.14) |
SMR standardized mortality ratio, CI confidence interval, COPD chronic obstructive pulmonary disease
#Statistical significance with P < 0.05
Fig. 2.
The percentages of main causes of death in kidney cancer patients. A1 Patients with localized kidney cancer. A2 Patients with localized clear cell RCC. A3 Patients with localized non-clear cell RCC. B1 Patients with regional kidney cancer. B2 Patients with regional clear cell RCC. B3 Patients with regional non-clear cell RCC
Fig. 3.
The mortality rate of main causes (including all causes of death, kidney cancer, SMTs and non-tumor causes) of death among patients with localized and regional kidney cancer with the year after diagnosis. A1 Mortality rate of main causes among patients with localized disease. A2 Mortality rate of main causes among patients with localized clear cell RCC. A3 Mortality rate of main causes among patients with localized non-clear cell RCC. B1 Mortality rate of main causes among patients with regional disease. B2 Mortality rate of main causes among patients with regional clear cell RCC. B3 Mortality rate of main causes among patients with regional non-clear cell RCC
Causes of death for patients with regional disease
Among the 29,602 patients with regional disease, 14,437 of them died during the follow-up. 10,348(71.7%) and 4089(28.3%) deaths occurred during the periods of < 5 years and > 5 years, respectively. 8,240 (57.1%) of all deaths were due to kidney cancer. SMTs and non-tumor causes accounted for 14.6% and 28.3% of all deaths, individually. Main SMTs included urinary bladder [n = 371, SMR: 10.90 (9.81–12.06)], lung and bronchus [n = 346, SMR: 1.21 (1.08–1.34)], and pancreas [n = 106, SMR: 1.57 (1.29–1.9)]. The main non-tumor causes included diseases of heart [n = 1,424, SMR: 1.26 (1.2–1.33)], cerebrovascular diseases [n = 289, SMR: 1.21 (1.08–1.36)], and diabetes mellitus [n = 227, SMR: 1.76 (1.54–2.0)]. The SMRs of deaths due to accidents, adverse effects, suicide and self-inflicted injury were not significantly improved. Patients with clear cell RCC did not exhibit an increased mortality risk of bladder cancer, lung and bronchus cancer and pancreas cancer, but patients with non-clear cell RCC did. Both groups had decreased mortality risk of prostate cancer. These results are presented in Table 3, Fig. 2B and Additional file 1. Mortality rates from SMT and non-tumor causes were similar in both groups and stabilized over time (Fig. 3B).
Table 3.
Main causes of deaths for patients with regional kidney cancer
| Causes of deaths | Total | Clear cell RCC | Non-clear cell RCC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Observed, n | Expected, n | SMR (95% CI) | Observed, n | Expected, n | SMR (95% CI) | Observed, n | Expected, n | SMR (95% CI) | |
| All causes of death | 14,437 | 4,292.43 | 3.36# (3.31–3.42) | 5,660 | 1,983.35 | 2.85# (2.78–2.93) | 8,777 | 2,309.08 | 3.80# (3.72–3.88) |
| All malignant cancers | 10,352 | 1,016.84 | 10.18# (9.99–10.38) | 3,918 | 487.27 | 8.04# (7.79–8.3) | 6,434 | 529.57 | 12.15# (11.85–12.45) |
| Urinary system | 8,746 | 61.07 | 143.22# (140.24–146.26) | 3,423 | 29.15 | 117.44# (113.54–121.44) | 5,323 | 31.92 | 166.77# (162.32–171.31) |
| Kidney and renal pelvis | 8,240 | 25.34 | 325.20# (318.21–332.3) | 3,410 | 12.36 | 275.95# (266.77–285.37) | 4,830 | 12.98 | 372.08# (361.66–382.72) |
| Urinary bladder | 371 | 34.05 | 10.90# (9.81–12.06) | 10 | 15.99 | 0.63 (0.3–1.15) | 361 | 18.06 | 19.99# (17.98–22.16) |
| Ureter | 57 | 0.8 | 71.17# (53.91–92.21) | 0 | 0.38 | 0 (0–9.7) | 57 | 0.42 | 135.53# (102.65–175.59) |
| Respiratory system | 354 | 295.99 | 1.20# (1.07–1.33) | 145 | 142.81 | 1.02 (0.86–1.19) | 209 | 153.19 | 1.36# (1.19–1.56) |
| Lung and bronchus | 346 | 286.72 | 1.21# (1.08–1.34) | 140 | 138.32 | 1.01 (0.85–1.19) | 206 | 148.41 | 1.39# (1.2–1.59) |
| Digestive System | 311 | 259.38 | 1.20# (1.07–1.34) | 119 | 125.56 | 0.95 (0.79–1.13) | 192 | 133.83 | 1.43# (1.24–1.65) |
| Pancreas | 106 | 67.4 | 1.57# (1.29–1.9) | 36 | 32.89 | 1.09 (0.77–1.52) | 70 | 34.51 | 2.03# (1.58–2.56) |
| Colon and rectum | 87 | 89.3 | 0.97 (0.78–1.2) | 35 | 41.94 | 0.83 (0.58–1.16) | 52 | 47.36 | 1.1 (0.82–1.44) |
| Liver and intrahepatic bile duct | 48 | 39.77 | 1.21 (0.89–1.6) | 23 | 20.15 | 1.14 (0.72–1.71) | 25 | 19.61 | 1.27 (0.82–1.88) |
| Male genital system | 46 | 78.63 | 0.59# (0.43–0.78) | 18 | 35.37 | 0.51# (0.3–0.8) | 28 | 43.26 | 0.65# (0.43–0.94) |
| Prostate | 43 | 77.58 | 0.55# (0.4–0.75) | 17 | 34.85 | 0.49# (0.28–0.78) | 26 | 42.73 | 0.61# (0.4–0.89) |
| Soft tissue including heart | 50 | 6.27 | 7.98# (5.92–10.51) | 2 | 3.08 | 0.65 (0.08–2.35) | 48 | 3.19 | 15.05# (11.1–19.96) |
| Brain and other nervous system | 44 | 22 | 2.00# (1.45–2.68) | 21 | 11.15 | 1.88# (1.17–2.88) | 23 | 10.86 | 2.12# (1.34–3.18) |
| Leukemia | 35 | 42.31 | 0.83 (0.58–1.15) | 10 | 20.05 | 0.50# (0.24–0.92) | 25 | 22.25 | 1.12 (0.73–1.66) |
| Lymphoma | 29 | 40.39 | 0.72 (0.48–1.03) | 13 | 19.15 | 0.68 (0.36–1.16) | 16 | 21.24 | 0.75 (0.43–1.22) |
| Non-tumor causes | |||||||||
| Diseases of heart | 1,424 | 1,128.76 | 1.26# (1.2–1.33) | 607 | 509.76 | 1.19# (1.1–1.29) | 817 | 619 | 1.32# (1.23–1.41) |
| Cerebrovascular diseases | 289 | 238.34 | 1.21# (1.08–1.36) | 129 | 105.6 | 1.22# (1.02–1.45) | 160 | 132.73 | 1.21# (1.03–1.41) |
| COPD and allied cond | 266 | 274.97 | 0.97 (0.85–1.09) | 104 | 129.15 | 0.81# (0.66–0.98) | 162 | 145.82 | 1.11 (0.95–1.3) |
| Diabetes mellitus | 227 | 129.1 | 1.76# (1.54–2) | 112 | 60.84 | 1.84# (1.52–2.22) | 115 | 68.25 | 1.68# (1.39–2.02) |
| Nephritis, nephrotic syndrome and nephrosis | 210 | 85.61 | 2.45# (2.13–2.81) | 90 | 38.64 | 2.33# (1.87–2.86) | 120 | 46.97 | 2.56# (2.12–3.06) |
| Pneumonia and influenza | 138 | 100 | 1.38# (1.16–1.63) | 48 | 44.17 | 1.09 (0.8–1.44) | 90 | 55.82 | 1.61# (1.3–1.98) |
| Alzheimer’s | 130 | 159.43 | 0.82# (0.68–0.97) | 60 | 69.31 | 0.87 (0.66–1.11) | 70 | 90.13 | 0.78# (0.61–0.98) |
| Accidents and adverse effects | 130 | 128.41 | 1.01 (0.85–1.2) | 53 | 61.93 | 0.86 (0.64–1.12) | 77 | 66.49 | 1.16 (0.91–1.45) |
| Septicemia | 108 | 61.91 | 1.74# (1.43–2.11) | 39 | 28.59 | 1.36 (0.97–1.86) | 69 | 33.32 | 2.07# (1.61–2.62) |
| Hypertension without heart disease | 89 | 47.89 | 1.86# (1.49–2.29) | 37 | 21.55 | 1.72# (1.21–2.37) | 52 | 26.34 | 1.97# (1.47–2.59) |
| Chronic liver disease and cirrhosis | 65 | 45.89 | 1.42# (1.09–1.81) | 35 | 24.07 | 1.45# (1.01–2.02) | 30 | 21.82 | 1.37 (0.93–1.96) |
| Suicide and self-inflicted injury | 33 | 32.71 | 1.01 (0.69–1.42) | 15 | 17.1 | 0.88 (0.49–1.45) | 18 | 15.62 | 1.15 (0.68–1.82) |
SMR standardized mortality ratio, CI confidence interval, COPD chronic obstructive pulmonary disease
#Statistical significance with P < 0.05
Discussion
In our study, we found that the increased incidence of kidney cancer from 2000 to 2017 was predominantly attributed to the growth of localized diseases. Because of the wide use of imaging technology including ultrasound, CT, MRI, etc., many early-stage kidney cancer were found by unintentional detection [11, 12]. A previous study reported that RCC incidence increased while renal pelvis cancer rate decreased over time in the US [13]. Our data showed that the incidence of kidney cancer increase with age and reached high levels after the age of 60 in both men and women. The incidence and mortality in females were obviously lower than that in males [12, 14]. It was reported that about half of all cases of kidney cancer were diagnosed among patients above 65 years old [1].
For the SMTs among kidney cancer patients, our results found that the most common SMTs were from lung and bronchus cancer, pancreas cancer, colon and rectum cancer, bladder cancer, prostate cancer, leukemia (mainly myeloid and monocytic leukemia), brain and other nervous system tumor and lymphoma (mainly non-Hodgkin’s lymphomas). A previous study based on 1,425 RCC cases with multiple primary cancers found that prostate, bladder, lung, breast, colon and rectal cancer, malignant melanomas and non-Hodgkin’s lymphomas were the most common SMTs [15]. An international collaborative study with a median of 11.6 years follow-up period found the standardized incidence ratios for solid tumors and leukemias after Wilms tumor were 5.1 and 5.0, respectively [16]. The most common SMTs were the digestive organs, breast, thyroid, bone and central nervous system. Another study with 447 patients undergoing nephrectomy for the primary renal tumor in Croatia found that the most common SMTs were prostate and colon carcinoma [17]. The reason these results differed from ours was that our study focused on the mortality of SMTs rather than the incidence. Although some SMTs such as pancreatic cancer and leukemia, were not common, their high mortality rates warrant sufficient attention.
Compared with the general population, our results showed that kidney cancer patients were associated with increased mortality risks in SMTs like pancreas cancer, liver and intrahepatic bile duct cancer, stomach cancer and nervous system tumors, and decreased mortality risk in prostate cancer and colon and rectum cancer. Some studies showed increased risks of lung, bladder, rectal, prostate, thyroid gland, adrenal gland and nervous system cancer and non-Hodgkin’s lymphoma in primary RCC patients [18–20]. A bidirectional association was found between thyroid cancer, breast cancer and kidney cancer, with a threefold and 1.5-fold increase in the prevalence of thyroid cancer in men and women with kidney cancer, respectively [21]. Our results firstly found that the increased mortality risk of bladder cancer among kidney cancer patients was due to the non-clear cell RCC patients. The patients with clear cell RCC patients did not have increased risks of bladder cancer when comparing with general population.
Among all causes of death, our results found that non-tumor causes accounted for 60.4% and 28.3% of localized and regional diseases. The most common causes included heart diseases, COPD and allied cond, cerebrovascular diseases, nephritis, nephrotic syndrome and nephrosis, and diabetes mellitus. In the current literature, there were few studies that evaluated the non-tumor causes of death among kidney cancer patients. An Australia study analyzed the non-cancer causes of death among all cancer patients [22]. Their results showed that nearly 50% of cancer patients were more likely to die of non-cancer causes and the major non-cancer causes included cardiovascular disease (coronary heart disease and stroke), respiratory diseases, diseases of the digestive system, injury and poisoning and endocrine, nutritional and metabolic diseases [22]. A study reported that cardiovascular disease death cases accounted for a more significant proportion than those who died of RCC (26.4% vs 22.5%) for RCC patients with localized stage [23]. Another study with the SEER data [3] showed that the most common non-cancer causes of death among all cancer patients was the heart disease, which accounted above 40% of all deaths [3]. In our study, the heart diseases accounted for 20.3% and 9.9% of all localized and regional kidney cancer deaths. Another study with Korean survivors of adult cancer showed that the leading specific non-tumor causes of death among all cancer patients were cerebrovascular disease, diabetes mellitus, ischemic heart disease, suicide, and chronic lower respiratory disease [24].
Our results showed that the mortality risks of heart diseases, cerebrovascular diseases, nephritis, nephrotic syndrome and nephrosis, diabetes mellitus, pneumonia and influenza, hypertension, septicemia, and chronic liver disease were significantly increased in all kidney cancer patients when comparing with general population. While the mortality risk of COPD was only increased in the non-clear cell RCC patients but not in clear cell RCC patients. All kidney patients were associated with lower mortality risk of Alzheimer. Increased mortality risk in some diseases might due to the impaired kidney function. The reduced kidney function was closely associated with the increased deaths from heart failure, valvular diseases, infectious and other causes [25]. It was reported that the mortality of sepsis had relation with the cancer. The mortality of cancer-related sepsis was 27.9% which was significantly higher than 19.5% of non-tumor-related sepsis [26]. There were some different results in previous studies. In Zaorsky et al. study [3], the SMR of above non-cancer causes were all significantly increased among cancer patients. The SMR of Alzheimer only decreased in the period of 2–11 months and 12–59 months after diagnosis. Besides, their SMR values were obviously higher than ours. However, in Shin et al. study [24], the risk for non-cancer death was significantly lower among long-term survivors (SMR, 0.78; 95% CI 0.76–0.80). The specific causes of death including diabetes mellitus, hypertensive diseases, heart diseases, and cerebrovascular disease, etc., were all decreased. The reason for the different mortality risk in different studies might due to the patient’s inclusion. Because there were so many causes of death, if there were not enough patients, the number of patients for each specific cause would be very limited. The results would be influenced and biased. Inconsistent age stratification of enrolled patients and normal populations can also affect SMR results. Young people were associated with less underlying diseases than the elderly. The proportion of young and elderly patients in the enrolled patient population could significantly affect the results of non-tumor causes of death. A study found that congestive heart failure, chronic kidney diseases, peripheral vascular diseases, COPD, diabetes and cerebrovascular diseases were associated with the decreased overall survival of localized kidney cancer patients [27]. In the USA, approximately 2/3 of medicare beneficiaries over age 65 have two or more chronic conditions, with 1/3 having four or more [28]. The increasing multimorbidity trend with age was associated with higher risks of death from non-cancer diseases [29].
Our study firstly provided the most comprehensive description of the risk of death from all causes in patients with different pathological type kidney cancer. Patients were analyzed, respectively, according to their different tumor stages and survival time. However, there were some limitations in our study. Firstly, we used Summary Stage 2000 (1998 +) to distinguish localized and regional cancer, but these classifications may not be the same in different periods. Therefore, the results of this study cannot fully represent the current staging results. Secondly, the treatment information of patients in this database was incomplete. The database only provided radiotherapy and chemotherapy records, but not detailed treatment information. There was no information about immunotherapy or targeted therapy. These treatments might have important impacts on the survival and prognosis of patients. Our results might be influenced by the missing information.
Conclusion
Our study provides a detailed analysis of the causes of death for patients with localized and regional kidney cancer after diagnosis, and the mortal risk for each cause. Diseases including lung and bronchus cancer, bladder cancer, pancreas cancer, colon and rectum cancer, diseases of heart, COPD, cerebrovascular diseases are the leading causes of death. After identifying the underlying causes of mortality, our study has the potential to facilitate interdisciplinary and multiprofessional collaborations that could significantly enhance prognosis and survival rates. Further research is required to elucidate the mechanisms behind the development of secondary malignancies and non-neoplastic diseases in patients with kidney cancer, as well as to explore differences between clear cell and non-clear cell renal carcinoma.
Supplementary Information
Additional file 1. Raw data used in the study.
Author contributions
Study design: PS, LY and QD; data collection: PS and XW; manuscript preparation: ZL and JZ; data analysis and interpretation: XW, JC and LY; manuscript draft: PS, LY and XW. All authors confirm that they read and approved the final draft for submission. All authors are also responsible for the manuscript content.
Funding
This work was supported by the Project of Science and Technology Department of Sichuan Province (2021YFS0117), and the National Key Research and Development Program of China (Grant No. 2021YFC2009304).
Availability of data and materials
The data of this study are available in the SEER database (https://seer.cancer.gov/). The raw data have been uploaded as the Additional file 1.
Declarations
Ethics approval and consent to participate
All data were obtained from the public database; no ethical approval was required.
Competing interests
The authors have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Luchen Yang, Xiaotian Wu and Jing Zhou have contributed equally to this work.
References
- 1.Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer. J Clin Oncol. 2018 doi: 10.1200/JCO.2018.79.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708. [DOI] [PubMed] [Google Scholar]
- 3.Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407. doi: 10.1093/annonc/mdw604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–530. doi: 10.1016/j.eururo.2014.10.002. [DOI] [PubMed] [Google Scholar]
- 5.Hancock SB, Georgiades CS. Kidney Cancer. Cancer J. 2016;22(6):387–392. doi: 10.1097/PPO.0000000000000225. [DOI] [PubMed] [Google Scholar]
- 6.Hancock SB. Georgiades CSJTCJ. Kidney cancer. 2016;22(6):387–392. doi: 10.1097/PPO.0000000000000225. [DOI] [PubMed] [Google Scholar]
- 7.Di Lascio G, Sciarra A, Del Giudice F, Salciccia S, Busetto GM, Berardinis E, et al. Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review. Cent Eur J Urol. 2022;75(1):14–27. doi: 10.5173/ceju.2021.0256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ebbing J, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, et al. Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer. BMC Nephrol. 2019;20(1):40. doi: 10.1186/s12882-019-1215-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Patel HD, Gupta M, Joice GA, Srivastava A, Alam R, Allaf ME, et al. Clinical stage migration and survival for renal cell carcinoma in the United States. Eur Urol Oncol. 2019;2(4):343–348. doi: 10.1016/j.euo.2018.08.023. [DOI] [PubMed] [Google Scholar]
- 10.Johnson CH PS, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. The 2007 Multiple Primary and Histology Coding Rules. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007.
- 11.Pinheiro PS, Medina HN, Callahan KE, Koru-Sengul T, Sharma J, Kobetz EN, et al. Kidney cancer mortality disparities among hispanics in the US. Cancer Epidemiol. 2021;72:101938. doi: 10.1016/j.canep.2021.101938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):2022. [PubMed] [Google Scholar]
- 13.Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257. doi: 10.1038/nrurol.2010.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Crocetto F, Buonerba C, Caputo V, Ferro M, Persico F, Trama F, et al. Urologic malignancies: advances in the analysis and interpretation of clinical findings. Future Sci OA. 2021;7(4):674. doi: 10.2144/fsoa-2020-0210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006;97(4):698–702. doi: 10.1111/j.1464-410X.2006.06004.x. [DOI] [PubMed] [Google Scholar]
- 16.Breslow NE, Lange JM, Friedman DL, Green DM, Hawkins MM, Murphy MF, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer. 2010;127(3):657–666. doi: 10.1002/ijc.25067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Turkic M, Znaor A, Novosel I, Reljic A, Belicza M, Kruslin B. Second primary malignant tumors in patients with primary renal cell carcinoma. Acta Med Croatica. 2005;59(2):91–95. [PubMed] [Google Scholar]
- 18.Kantor AF, McLaughlin JK, Curtis RE, Flannery JT, Fraumeni JF., Jr Risk of second malignancy after cancers of the renal parenchyma, renal pelvis, and ureter. Cancer. 1986;58(5):1158–1161. doi: 10.1002/1097-0142(19860901)58:5<1158::AID-CNCR2820580530>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- 19.Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database. J Urol. 2011;185(6):2045–2049. doi: 10.1016/j.juro.2011.02.001. [DOI] [PubMed] [Google Scholar]
- 20.Tihan T, Filippa DA. Coexistence of renal cell carcinoma and malignant lymphoma. A causal relationship or coincidental occurrence? Cancer. 1996;77(11):2325–2331. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2325::AID-CNCR22>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
- 21.Van Fossen VL, Wilhelm SM, Eaton JL, McHenry CR. Association of thyroid, breast and renal cell cancer: a population-based study of the prevalence of second malignancies. Ann Surg Oncol. 2013;20(4):1341–1347. doi: 10.1245/s10434-012-2718-3. [DOI] [PubMed] [Google Scholar]
- 22.Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia) Cancer Causes Control. 2006;17(3):287–297. doi: 10.1007/s10552-005-0530-0. [DOI] [PubMed] [Google Scholar]
- 23.Zhan X, Chen T, Liu Y, Wan H, Liu X, Deng X, et al. Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study. BMC Public Health. 2023;23(1):770. doi: 10.1186/s12889-023-15647-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Shin DW, Ahn E, Kim H, Park S, Kim YA, Yun YH. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control. 2010;21(6):919–929. doi: 10.1007/s10552-010-9521-x. [DOI] [PubMed] [Google Scholar]
- 25.Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504–2511. doi: 10.1681/ASN.2014070714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Hensley MK, Donnelly JP, Carlton EF, Prescott HC. Epidemiology and outcomes of cancer-related versus non-cancer-related sepsis hospitalizations. Crit Care Med. 2019;47(10):1310–1316. doi: 10.1097/CCM.0000000000003896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Patel HD, Kates M, Pierorazio PM, Gorin MA, Jayram G, Ball MW, et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol. 2014;21(11):1086–1092. doi: 10.1111/iju.12527. [DOI] [PubMed] [Google Scholar]
- 28.Centers for Medicare and Medicaid Services. Chronic Conditions among Medicare Beneficiaries, Chartbook, 2012 Edition. Baltimore, MD. 2012;11:15–21.
- 29.Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14(Suppl 1):28–32. doi: 10.1080/13814780802436093. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1. Raw data used in the study.
Data Availability Statement
The data of this study are available in the SEER database (https://seer.cancer.gov/). The raw data have been uploaded as the Additional file 1.